

Philip C Robinson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3906897/publications.pdf>

Version: 2024-02-01

158
papers

7,545
citations

81743

39
h-index

64668

79
g-index

165
all docs

165
docs citations

165
times ranked

9226
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 859-866.	0.5	908
2	Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. <i>Nature Genetics</i> , 2013, 45, 730-738.	9.4	699
3	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942.	0.5	496
4	Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 686-691.	2.9	340
5	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. <i>Nature Communications</i> , 2015, 6, 7146.	5.8	220
6	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , The, 2020, 2, e250-e253.	2.2	172
7	Glossary of terms for musculoskeletal radiology. <i>Skeletal Radiology</i> , 2020, 49, 1-33.	1.2	163
8	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.5	151
9	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , 2021, 7, e001814.	1.8	121
10	Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. <i>Lancet Rheumatology</i> , The, 2020, 2, e653-e655.	2.2	119
11	Genetic Dissection of Acute Anterior Uveitis Reveals Similarities and Differences in Associations Observed With Ankylosing Spondylitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 140-151.	2.9	114
12	Genetics of ankylosing spondylitis. <i>Molecular Immunology</i> , 2014, 57, 2-11.	1.0	109
13	COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. <i>Nature Reviews Rheumatology</i> , 2022, 18, 191-204.	3.5	105
14	Imaging of Muscle Injuries in Sports Medicine: Sports Imaging Series. <i>Radiology</i> , 2017, 282, 646-663.	3.6	104
15	Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. <i>Arthritis Research and Therapy</i> , 2020, 22, 28.	1.6	104
16	Sonography of Common Tendon Injuries. <i>American Journal of Roentgenology</i> , 2009, 193, 607-618.	1.0	97
17	COVID-19 therapeutics: Challenges and directions for the future. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2119893119.	3.3	92
18	The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. <i>Med</i> , 2020, 1, 90-102.	2.2	87

#	ARTICLE	IF	CITATIONS
19	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Mulhearn et al. Annals of the Rheumatic Diseases, 2023, 82, e116-e116.	0.5	87
20	ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients. Annals of the Rheumatic Diseases, 2015, 74, 1627-1629.	0.5	86
21	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open, 2021, 4, e2129639.	2.8	86
22	The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. Nature Reviews Rheumatology, 2020, 16, 293-294.	3.5	85
23	An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. Journal of Rheumatology, 2015, 42, 1702-1707.	1.0	79
24	Systematic review of the prevalence of gout and hyperuricaemia in Australia. Internal Medicine Journal, 2012, 42, 997-1007.	0.5	76
25	COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. , 2021, 9, e002630.		76
26	Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis. Annals of the Rheumatic Diseases, 2013, 72, 162-164.	0.5	75
27	Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis Care and Research, 2019, 71, 427-434.	1.5	73
28	Axial spondyloarthritis: concept, construct, classification and implications for therapy. Nature Reviews Rheumatology, 2021, 17, 109-118.	3.5	73
29	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Annals of the Rheumatic Diseases, 2019, 78, 1592-1600.	0.5	72
30	Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Annals of the Rheumatic Diseases, 2020, 79, 1386-1388.	0.5	67
31	Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009. Rheumatology, 2013, 52, 118-126.	0.9	66
32	Gout " An update of aetiology, genetics, co-morbidities and management. Maturitas, 2018, 118, 67-73.	1.0	66
33	Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis and Rheumatology, 2021, 73, 374-380.	2.9	66
34	Gout: Joints and beyond, epidemiology, clinical features, treatment and co-morbidities. Maturitas, 2014, 78, 245-251.	1.0	64
35	Impingement syndromes of the ankle. European Radiology, 2007, 17, 3056-3065.	2.3	60
36	SAPHO and CRMO: The Value of Imaging. Seminars in Musculoskeletal Radiology, 2018, 22, 207-224.	0.4	57

#	ARTICLE	IF	CITATIONS
37	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert Review of Clinical Immunology, 2020, 16, 659-666.	1.3	57
38	The window of opportunity: a relevant concept for axial spondyloarthritis. Arthritis Research and Therapy, 2014, 16, 109.	1.6	53
39	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals of the Rheumatic Diseases, 2022, 81, 970-978.	0.5	49
40	The Genetics of Ankylosing Spondylitis and Axial Spondyloarthritis. Rheumatic Disease Clinics of North America, 2012, 38, 539-553.	0.8	47
41	Insight into rheumatological cause and effect through the use of Mendelian randomization. Nature Reviews Rheumatology, 2016, 12, 486-496.	3.5	46
42	Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. Current Opinion in Rheumatology, 2020, 32, 434-440.	2.0	46
43	Waiting for JAK inhibitor safety data. RMD Open, 2022, 8, e002236.	1.8	46
44	Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci. , 2020, 61, 3.		43
45	Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease. American Journal of Medicine, 2022, 135, 32-38.	0.6	41
46	Diffusion-weighted Imaging Is a Sensitive and Specific Magnetic Resonance Sequence in the Diagnosis of Ankylosing Spondylitis. Journal of Rheumatology, 2018, 45, 771-778.	1.0	40
47	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatology, The, 2021, 3, e707-e714.	2.2	40
48	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology, 2022, 61, SI143-SI150.	0.9	40
49	The ASAS Criteria for Axial Spondyloarthritis: Strengths, Weaknesses, and Proposals for a Way Forward. Current Rheumatology Reports, 2015, 17, 62.	2.1	39
50	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatology, The, 2021, 3, e855-e864.	2.2	38
51	Conventional 3-T MRI and 1.5-T MR Arthrography of Femoroacetabular Impingement. American Journal of Roentgenology, 2012, 199, 509-515.	1.0	37
52	Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank. ACR Open Rheumatology, 2021, 3, 333-340.	0.9	37
53	Time to Treatment in Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2010, 16, 267-273.	0.5	36
54	Rothia aerea as a Cause of Sepsis in a Native Joint. Journal of Clinical Microbiology, 2010, 48, 2648-2650.	1.8	35

#	ARTICLE	IF	CITATIONS
55	Endoplasmic reticulum aminopeptidases in the pathogenesis of ankylosing spondylitis: Fig. 1. <i>Rheumatology</i> , 2015, 54, 1549-1556.	0.9	35
56	<i>Festina lente</i> : hydroxychloroquine, COVID-19 and the role of the rheumatologist. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 734-736.	0.5	35
57	The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance. <i>Rheumatology</i> , 2020, 59, 1204-1206.	0.9	34
58	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187.	1.8	34
59	The genetic associations of acute anterior uveitis and their overlap with the genetics of ankylosing spondylitis. <i>Genes and Immunity</i> , 2016, 17, 46-51.	2.2	33
60	The intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 202-212.	1.4	32
61	Exome-wide study of ankylosing spondylitis demonstrates additional shared genetic background with inflammatory bowel disease. <i>Npj Genomic Medicine</i> , 2016, 1, 16008.	1.7	32
62	Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy. <i>Rheumatology and Therapy</i> , 2019, 6, 165-177.	1.1	32
63	The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. <i>Rheumatology</i> , 2021, 60, 353-358.	0.9	32
64	A qualitative and quantitative analysis of the characteristics of gout patient education resources. <i>Clinical Rheumatology</i> , 2013, 32, 771-778.	1.0	30
65	Do MRI and ultrasound of the anterior pelvis correlate with, or predict, young football players's clinical findings? A 4-year prospective study of elite academy soccer players. <i>British Journal of Sports Medicine</i> , 2015, 49, 176-182.	3.1	30
66	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>Lancet Rheumatology</i> , The, 2022, 4, e237-e240.	2.2	30
67	Disease-associated polymorphisms in ERAP1 do not alter endoplasmic reticulum stress in patients with ankylosing spondylitis. <i>Genes and Immunity</i> , 2015, 16, 35-42.	2.2	29
68	SARS CoV-2 infection among patients using immunomodulatory therapies. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 269-271.	0.5	29
69	Shear-Wave Elastography of Benign versus Malignant Musculoskeletal Soft-Tissue Masses: Comparison with Conventional US and MRI. <i>Radiology</i> , 2019, 290, 410-417.	3.6	28
70	Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101657.	1.4	28
71	Classification Criteria: Peripheral Spondyloarthropathy and Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2013, 15, 317.	2.1	26
72	Advances in pharmacotherapy for the treatment of gout. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 533-546.	0.9	26

#	ARTICLE	IF	CITATIONS
73	Epidemiology of inpatient gout in Australia and New Zealand: temporal trends, comorbidities and gout flare site. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 779-784.	0.9	26
74	Capturing Patient-Reported Outcomes During the COVID-19 Pandemic: Development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey. <i>Arthritis Care and Research</i> , 2020, 72, 871-873.	1.5	25
75	Divergent effects of acute versus chronic glucocorticoids in COVID-19. <i>Lancet Rheumatology, The</i> , 2021, 3, e168-e170.	2.2	24
76	Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 733-745.	0.9	24
77	Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based Study. <i>Journal of Rheumatology</i> , 2022, 49, 320-329.	1.0	24
78	Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1185-1204.	1.3	23
79	The prevalence of gout and hyperuricaemia in Australia: An updated systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 121-128.	1.6	23
80	Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2021, 48, 1053-1059.	1.0	22
81	Febuxostat for the treatment of hyperuricaemia in gout. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1289-1299.	0.9	20
82	Imaging Athletic Groin Pain. <i>Radiologic Clinics of North America</i> , 2016, 54, 865-873.	0.9	19
83	Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study. <i>Lancet Rheumatology, The</i> , 2022, 4, e274-e281.	2.2	19
84	ERAP2 functional knockout in humans does not alter surface heavy chains or HLA-B27, inflammatory cytokines or endoplasmic reticulum stress markers. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2092-2095.	0.5	18
85	Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. <i>Lancet Rheumatology, The</i> , 2021, 3, e71-e82.	2.2	18
86	Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1091-1093.	0.5	16
87	Genetic diagnostic profiling in axial spondyloarthritis: a real world study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 229-233.	0.4	16
88	Patients with gout: an under-recognised group at high risk of COVID-19. <i>Lancet Rheumatology, The</i> , 2021, 3, e317-e318.	2.2	15
89	EVOLVE: The Australian Rheumatology Association's "top five" list of investigations and interventions doctors and patients should question. <i>Internal Medicine Journal</i> , 2018, 48, 135-143.	0.5	13
90	ERAP1 biology and assessment in Ankylosing Spondylitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1816.	3.3	12

#	ARTICLE	IF	CITATIONS
91	Lesinurad for the treatment of hyperuricaemia in people with gout. Expert Opinion on Pharmacotherapy, 2017, 18, 1875-1881.	0.9	12
92	The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring. Journal of Rheumatology, 2018, 45, 697-704.	1.0	12
93	Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. Current Opinion in Rheumatology, 2021, 33, 111-116.	2.0	12
94	Poor Compliance with Community-Acquired Pneumonia Antibiotic Guidelines in a Large Australian Private Hospital Emergency Department. Microbial Drug Resistance, 2014, 20, 561-567.	0.9	11
95	COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: "Correspondence on "Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry" by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials " a real-world district general hospital experience" by K. Annals of the Rheumatic Diseases, 2020, 39, arhmd-2020-218713.	0.5	11
96	Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA). International Journal of Rheumatic Diseases, 2014, 17, 548-556.	0.9	10
97	MR Imaging of Impingement and Entrapment Syndromes of the Foot and Ankle. Magnetic Resonance Imaging Clinics of North America, 2017, 25, 145-158.	0.6	10
98	Changing COVID-19 outcomes in patients with rheumatic disease"are we really getting better at this?. Lancet Rheumatology, The, 2021, 3, e88-e90.	2.2	10
99	A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections. Seminars in Arthritis and Rheumatism, 2021, 51, 101-112.	1.6	10
100	Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry. Global Rheumatology, 0, ,.	0.0	10
101	Conducting research in a pandemic: The power of social media. European Journal of Rheumatology, 2020, 7, S85-S88.	1.3	10
102	Consensus statements on the imaging of axial spondyloarthritis in Australia and New Zealand. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 58-69.	0.9	9
103	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. Journal of Rheumatology, 2022, 49, 110-114.	1.0	9
104	Gout and the COVID-19 pandemic. Current Opinion in Rheumatology, 2022, 34, 111-117.	2.0	9
105	Response to: "Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis" by Gyrfi et al. Annals of the Rheumatic Diseases, 2021, 80, e88-e88.	0.5	8
106	What does endemic COVID-19 mean for the future of rituximab?. Lancet Rheumatology, The, 2022, 4, e3-e5.	2.2	8
107	The management of gout: Much has changed. Australian Family Physician, 2016, 45, 299-302.	0.5	8
108	Predictors of hospitalization in patients with rheumatic disease and COVID-19 in Ireland: data from the COVID-19 global rheumatology alliance registry. Rheumatology Advances in Practice, 2021, 5, rkab031.	0.3	7

#	ARTICLE	IF	CITATIONS
109	Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis” by van Vollenhoven <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e178-e178.	0.5	7
110	The impact of COVID-19 on rheumatology training—results from the COVID-19 Global Rheumatology Alliance trainee survey. <i>Rheumatology Advances in Practice</i> , 2022, 6, rrac001.	0.3	7
111	Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry. <i>Rheumatology</i> , 2022, 61, SI151-SI156.	0.9	7
112	Management of patients with gout and achievement of target serum urate levels at a tertiary rheumatology service in Australia. <i>Internal Medicine Journal</i> , 2020, 50, 337-341.	0.5	6
113	Cost-Effectiveness of Colchicine Prophylaxis for Gout Flares When Commencing Allopurinol. <i>Arthritis Care and Research</i> , 2021, 73, 1537-1543.	1.5	6
114	Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. <i>Current Opinion in Rheumatology</i> , 2021, 33, 412-418.	2.0	6
115	Management of autoimmune disease during the COVID-19 pandemic. <i>Australian Prescriber</i> , 2020, 43, 146-147.	0.5	6
116	Rapid Adoption of Telemedicine in Rheumatology Care During the COVID-19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees. <i>ACR Open Rheumatology</i> , 2022, 4, 128-133.	0.9	6
117	Role of genetics in infection-associated arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 213-225.	1.4	5
118	Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial spondyloarthritis. <i>Internal Medicine Journal</i> , 2015, 45, 127-133.	0.5	5
119	Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: “Correspondence on “Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry” by Gianfrancesco <i>et al</i> . Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases” by Giollo <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e223-e223.	0.5	5
120	Biologic therapy for uveitis: addressing access issues is paramount. <i>Internal Medicine Journal</i> , 2020, 50, 508-509.	0.5	5
121	Response to: “Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine” by Carbillon <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e55-e55.	0.5	5
122	Value-Based Healthcare in Rheumatology: Axial Spondyloarthritis and Beyond. <i>Current Rheumatology Reports</i> , 2021, 23, 36.	2.1	5
123	Sulfasalazine: a risk factor for severe COVID-19?. <i>Lancet Rheumatology, The</i> , 2022, , .	2.2	5
124	A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic. <i>ACR Open Rheumatology</i> , 2020, 2, 491-495.	0.9	4
125	Inter- and intra-reader reproducibility of shear wave elastography measurements for musculoskeletal soft tissue masses. <i>Skeletal Radiology</i> , 2020, 49, 779-786.	1.2	4
126	The effect of reducing systemic inflammation on serum urate. <i>Rheumatology</i> , 2020, 59, 3108-3109.	0.9	4

#	ARTICLE	IF	CITATIONS
127	Healthcare access and attitudes towards telehealth during the early phase of the COVID-19 pandemic among an Australian cohort with inflammatory arthritis. <i>Internal Medicine Journal</i> , 2021, 51, 788-792.	0.5	4
128	Association of Crohn's disease-related chromosome 1q32 with ankylosing spondylitis is independent of bowel symptoms and faecal calprotectin. <i>PeerJ</i> , 2018, 6, e5088.	0.9	4
129	Severe hypothermia in association with sodium valproate overdose. <i>New Zealand Medical Journal</i> , 2005, 118, U1681.	0.5	4
130	Racial and ethnic differences in COVID-19 outcomes: a call to action. <i>Lancet Rheumatology</i> , The, 2022, 4, e455-e457.	2.2	4
131	Decreasing time to treatment in rheumatoid arthritis: review of delays in presentation, referral and assessment. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 173-187.	0.3	3
132	Top-Ten Tips for Imaging Groin Injury in Athletes. <i>Seminars in Musculoskeletal Radiology</i> , 2019, 23, 361-375.	0.4	3
133	Time to recognise gout as a chronic disease. <i>Medical Journal of Australia</i> , 2020, 212, 285.	0.8	3
134	Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e158-e158.	0.5	3
135	Non-neoplastic Soft Tissue Tumors and Tumor-like Lesions. <i>Seminars in Musculoskeletal Radiology</i> , 2020, 24, 645-666.	0.4	3
136	Venous thromboembolism in medical inpatients—the silent epidemic of neglect. <i>Journal of the Royal Society of Medicine</i> , 2005, 98, 484-485.	1.1	2
137	Does midlife obesity really lower dementia risk?. <i>Lancet Diabetes and Endocrinology</i> , the, 2015, 3, 501.	5.5	2
138	Predictors of Success in Gout Treatment. <i>Journal of Rheumatology</i> , 2020, 47, 313-315.	1.0	2
139	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Arnaud and Devilliers. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e114-e114.	0.5	2
140	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Rosenbaum et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e139-e139.	0.5	2
141	Dr. Conway et al reply. <i>Journal of Rheumatology</i> , 2021, , jrheum.210913.	1.0	2
142	Early impacts of the COVID-19 pandemic on children with pediatric rheumatic diseases. <i>European Journal of Rheumatology</i> , 2023, 9, 185-190.	1.3	2
143	Venous Thromboembolism in Medical Inpatients—the Silent Epidemic of Neglect. <i>Journal of the Royal Society of Medicine</i> , 2005, 98, 484-485.	1.1	1
144	Management of thyroid disease in pregnancy — Room for improvement in the first trimester. <i>Obstetric Medicine</i> , 2016, 9, 126-129.	0.5	1

#	ARTICLE	IF	CITATIONS
145	The COVID-19 Pandemic and Rheumatology: Impact on Providing Care in Latin America and Around the World. <i>Journal of Rheumatology</i> , 2021, 48, 1501-1503.	1.0	1
146	Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis. <i>Rheumatology and Therapy</i> , 2021, 8, 1603-1616.	1.1	1
147	The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C-reactive Protein Levels. <i>ACR Open Rheumatology</i> , 2021, 3, 699-706.	0.9	1
148	Emerging evidence for the use of colchicine for secondary prevention of coronary heart disease. <i>Medical Journal of Australia</i> , 2022, , .	0.8	1
149	Australian Consensus Statements for the Assessment and Management of Non-radiographic Axial Spondyloarthritis. <i>Rheumatology and Therapy</i> , 2022, 9, 1-24.	1.1	1
150	Minimal Impact of the COVID-19 Pandemic on Disease Activity and Health-Related Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b Open-Label Extension Study. <i>ACR Open Rheumatology</i> , 0, , .	0.9	1
151	Adherence to allopurinol in patients with gout: further insights generate further questions. <i>Lancet Rheumatology</i> , The, 2020, 2, e249-e250.	2.2	0
152	Gout models of care: The next step is to facilitate implementation. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1115-1116.	0.9	0
153	Author reply. <i>Internal Medicine Journal</i> , 2020, 50, 387-387.	0.5	0
154	Addressing the challenges of the SARS-CoV-2 pandemic in patients affected by autoimmune and rheumatic disease. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101664.	1.4	0
155	COVID-19 vaccination for people with autoimmune inflammatory rheumatic diseases on immunomodulatory therapies. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	0
156	Longitudinal development of incident gout from low-normal baseline serum urate concentrations: individual participant data analysis. <i>BMC Rheumatology</i> , 2021, 5, 33.	0.6	0
157	Dr. Conway et al reply. <i>Journal of Rheumatology</i> , 2022, 49, 120.2-121.	1.0	0
158	Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-reactive Protein Status: An Analysis From the CaSpAnd Study. <i>ACR Open Rheumatology</i> , 0, , .	0.9	0